Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Although clinical trials and real-world studies have affirmed the effectiveness and safety of the FDA-authorized COVID-19 vaccines, reports of breakthrough infections and persistent emergence of new variants highlight the need to vigilantly monitor the effectiveness of these vaccines. Here we compare the effectiveness of two full-length Spike protein-encoding mRNA vaccines from Moderna (mRNA-1273) and Pfizer/BioNTech (BNT162b2) in the Mayo Clinic Health System over time from January to July 2021, during which either the Alpha or Delta variant was highly prevalent. We defined cohorts of vaccinated and unvaccinated individuals from Minnesota (n = 25,589 each) matched on age, sex, race, history of prior SARS-CoV-2 PCR testing, and date of full vaccination. Both vaccines were highly effective during this study period against SARS-CoV-2 infection (mRNA-1273: 86%, 95%CI: 81-90.6%; BNT162b2: 76%, 95%CI: 69-81%) and COVID-19 associated hospitalization (mRNA-1273: 91.6%, 95% CI: 81-97%; BNT162b2: 85%, 95% CI: 73-93%). In July, vaccine effectiveness against hospitalization has remained high (mRNA-1273: 81%, 95% CI: 33-96.3%; BNT162b2: 75%, 95% CI: 24-93.9%), but effectiveness against infection was lower for both vaccines (mRNA-1273: 76%, 95% CI: 58-87%; BNT162b2: 42%, 95% CI: 13-62%), with a more pronounced reduction for BNT162b2. Notably, the Delta variant prevalence in Minnesota increased from 0.7% in May to over 70% in July whereas the Alpha variant prevalence decreased from 85% to 13% over the same time period. Comparing rates of infection between matched individuals fully vaccinated with mRNA-1273 versus BNT162b2 across Mayo Clinic Health System sites in multiple states (Minnesota, Wisconsin, Arizona, Florida, and Iowa), mRNA-1273 conferred a two-fold risk reduction against breakthrough infection compared to BNT162b2 (IRR = 0.50, 95% CI: 0.39-0.64). In Florida, which is currently experiencing its largest COVID-19 surge to date, the risk of infection in July after full vaccination with mRNA-1273 was about 60% lower than after full vaccination with BNT162b2 (IRR: 0.39, 95% CI: 0.24-0.62). Our observational study highlights that while both mRNA COVID-19 vaccines strongly protect against infection and severe disease, further evaluation of mechanisms underlying differences in their effectiveness such as dosing regimens and vaccine composition are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 3×
“The columns are: (1) Outcome: the clinical metric of COVID-19 severity assessed in the given row; (1) mRNA-1273 Breakthrough Cohort: cumulative incidence of the given outcome among mRNA-1273 breakthrough cases; (2) Prevalence in BNT162b2 Breakthrough Cohort: cumulative incidence of the given outcome among mRNA-1273 br…”
BackgroundEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“(6-8) Incidence Rate Ratio: Incidence Rate of the given vaccinated cohort divided by the Incidence Rate of the unvaccinated cohort, along with the exact 95% confidence interval.”
BackgroundReduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
Bland, J. M., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.328.7447.1073 · Cited by 928
Pawlowski, C., Lenehan, P., Puranik, A., Agarwal, V., Venkatakrishnan, A. J., Niesen, M. J. M., O’Horo, J. C., Virk, A., Swift, M. D., Badley, A. D., et al. (2021) · Med · doi:10.1016/j.medj.2021.06.007 · Cited by 187
Self-citation
Cited by
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169
Waning Immunity after the BNT162b2 Vaccine in Israel
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K.-H., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2027160 · Cited by 406
Nasreen, S., Chung, H., He, S., Brown, K. A., Gubbay, J. B., Buchan, S. A., Fell, D. B., Austin, P. C., Schwartz, K. L., Sundaram, M. E., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01053-0 · Cited by 344
SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Lipsitch, M., Krammer, F., Regev-Yochay, G., Lustig, Y., & Balicer, R. D. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00662-4 · Cited by 336
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
Lin, D.-Y., Gu, Y., Wheeler, B., Young, H., Holloway, S., Sunny, S.-K., Moore, Z., & Zeng, D. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117128 · Cited by 333
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
Goldblatt, D., Alter, G., Crotty, S., & Plotkin, S. A. (2022) · Immunological Reviews · doi:10.1111/imr.13091 · Cited by 298
Nanduri, S., Pilishvili, T., Derado, G., Soe, M. M., Dollard, P., Wu, H., Li, Q., Bagchi, S., Dubendris, H., Link-Gelles, R., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7034e3 · Cited by 286
Zeng, B., Gao, L., Zhou, Q., Yu, K., & Sun, F. (2022) · BMC Medicine · doi:10.1186/s12916-022-02397-y · Cited by 275
mRNA Vaccines in the COVID-19 Pandemic and Beyond
Hogan, M. J., & Pardi, N. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042420-112725 · Cited by 256
Kremsner, P. G., Ahuad Guerrero, R. A., Arana-Arri, E., Aroca Martinez, G. J., Bonten, M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00677-0 · Cited by 172
Chu, L., Montefiori, D., Huang, W., Nestorova, B., Chang, Y., Carfi, A., Edwards, D. K., Oestreicher, J., Legault, H., Girard, B., et al. (2021) · doi:10.1101/2021.09.29.21264089 · Cited by 105
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Ying, B., Whitener, B., VanBlargan, L. A., Hassan, A. O., Shrihari, S., Liang, C.-Y., Karl, C. E., Mackin, S., Chen, R. E., Kafai, N. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abm3302 · Cited by 85
“Our observation of B.1.617.2 infection and lung disease in low-dose mRNA-vaccinated K18-hACE2 mice corresponds to descriptions of B.1.617.2 breakthrough infections in vaccinated humans, some of which have required hospitalization (30, 31).”
InfluentialThe Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis
Zou, Y., Huang, D., Jiang, Q., Guo, Y., & Chen, C. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.940956 · Cited by 52
“Although the effectiveness of the currently available vaccines against new variants may decrease, vaccination still provides protection against severe COVID-19 caused by different variants (31, 32) and may also decrease the emergence of new variants.”
Background(2022) · doi:10.1186/s12916-022-02480-4 · Cited by 43
Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
Straus, W., Urdaneta, V., Esposito, D. B., Mansi, J. A., Sanz Rodriguez, C., Burton, P., & Vega, J. M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac446 · Cited by 41
Kremsner, P. G., Guerrero, R. A. A., Arana, E., Aroca Martinez, G. J., Bonten, M. J. M., Chandler, R., Corral, G., De Block, E. J. L., Ecker, L., Gabor, J. J., et al. (2021) · doi:10.2139/ssrn.3911826 · Cited by 17
(2022) · doi:10.1101/2022.03.29.22273086 · Cited by 4
(2021) · doi:10.1101/2021.11.12.21266222 · Cited by 1
Metadata
- Authors
- Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-Garcia, J., O’Horo, J. C., Virk, A., Swift, M. D., Halamka, J., Badley, A. D., Venkatakrishnan, A. J., & Soundararajan, V.
- Venue
- medRxiv
- Publisher
- openRxiv
- Published
- 2021-08-08
- OpenAlex
- W3190634807
- Cited by
- 255
- References
- 15
- Type
- posted content
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.